Similar articles for PMID: 18549463

Year	Number of Results
1989	1
1995	1
1998	1
1999	5
2000	3
2001	8
2002	1
2003	8
2004	5
2005	14
2006	19
2007	17
2008	30
2009	32
2010	28
2011	35
2012	24
2013	19
2014	24
2015	25
2016	13
2017	13
2018	3
2019	4
2021	1
2022	3
2024	0

1

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.

Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Tame MR, Piscaglia F, Andreone P; Bologna Liver Transplantation Group (BLTG); Ballardini G, Bernardi M, Bianchi FB, Biselli M, Bolondi L, Cescon M, Colecchia A, D'Errico A, Del Gaudio M, Ercolani G, Grazi GL, Grigioni W, Lorenzini S, Pinna AD, Ravaioli M, Roda E, Sama C, Vivarelli M. Lodato F, et al. Aliment Pharmacol Ther. 2008 Aug 15;28(4):450-7. doi: 10.1111/j.1365-2036.2008.03761.x. Epub 2008 Jun 11. Aliment Pharmacol Ther. 2008. PMID: 18549463 Free article. Clinical Trial.

2

Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.

Malone DC, Tran TT, Poordad FF. Malone DC, et al. J Manag Care Pharm. 2005 Oct;11(8):687-94. doi: 10.18553/jmcp.2005.11.8.687. J Manag Care Pharm. 2005. PMID: 16194133 Free PMC article.

3

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Hanouneh IA, et al. Liver Transpl. 2008 Jan;14(1):53-8. doi: 10.1002/lt.21312. Liver Transpl. 2008. PMID: 18161839 Free article.

4

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.

Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, Ciećko-Michalska I. Mach TH, et al. Pol Arch Med Wewn. 2011 Dec;121(12):434-9. Pol Arch Med Wewn. 2011. PMID: 22157768 Free article. Clinical Trial.

5

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.

Sood A, Midha V, Hissar S, Kumar M, Suneetha PV, Bansal M, Sood N, Sakhuja P, Sarin SK. Sood A, et al. J Gastroenterol Hepatol. 2008 Feb;23(2):203-7. doi: 10.1111/j.1440-1746.2007.05057.x. Epub 2007 Jul 20. J Gastroenterol Hepatol. 2008. PMID: 17645472 Clinical Trial.

6

High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.

Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB. Faisal N, et al. Hepatol Int. 2015 Jan;9(1):76-83. doi: 10.1007/s12072-014-9589-6. Epub 2014 Nov 29. Hepatol Int. 2015. PMID: 25788382

7

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.

Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M. Kamal SM, et al. Liver Int. 2011 Mar;31(3):401-11. doi: 10.1111/j.1478-3231.2010.02435.x. Epub 2011 Jan 11. Liver Int. 2011. PMID: 21281434 Clinical Trial.

8

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators. Angelico M, et al. Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c. Eur J Gastroenterol Hepatol. 2008. PMID: 18679072 Clinical Trial.

9

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D. Gallegos-Orozco JF, et al. Rev Invest Clin. 2003 Mar-Apr;55(2):138-42. Rev Invest Clin. 2003. PMID: 12827916

10

The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.

Napoli N, Giannelli G, Antonaci A, Antonaci S. Napoli N, et al. J Viral Hepat. 2008 Apr;15(4):300-4. doi: 10.1111/j.1365-2893.2007.00944.x. J Viral Hepat. 2008. PMID: 18307592 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

302 results

Results by year